Eli Lilly and Company

224.09-9.45-4.05%Vol 5.61M1Y Perf 55.26%
Jun 11th, 2021 16:02 DELAYED
BID222.50 ASK224.95
Open227.03 Previous Close233.54
Pre-Market- After-Market224.09
 - -  - -%
Target Price
208.82 
Analyst Rating
Moderate Buy 1.67
Potential %
-6.81 
Finscreener Ranking
★★     45.76
Insiders Trans % 3/6/12 mo.
100/100/-43 
Value Ranking
★+     44.78
Insiders Value % 3/6/12 mo.
100/100/-93 
Growth Ranking
★★★+     56.83
Insiders Shares Cnt. % 3/6/12 mo.
100/100/-93 
Income Ranking
★+     36.02
Market Cap214.91B 
Earnings Rating
Sell
Price Range Ratio 52W %
88.97 
Earnings Date
29th Jul 2021

Today's Price Range

221.56229.59

52W Range

129.21235.85

5 Year PE Ratio Range

-409.4043.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
10.92%
1 Month
15.99%
3 Months
7.69%
6 Months
40.02%
1 Year
55.26%
3 Years
162.12%
5 Years
204.96%
10 Years
607.70%

TickerPriceChg.Chg.%
LLY224.09-9.4500-4.05
AAPL127.351.24000.98
GOOG2 513.93-7.6700-0.30
MSFT257.890.65000.25
XOM62.17-0.5800-0.92
WFC45.680.59001.31
JNJ164.96-2.1200-1.27
FB331.26-1.2000-0.36
GE13.690.06000.44
JPM160.29-0.1100-0.07
Financial StrengthValueIndustryS&P 500US Markets
0.80
1.40
0.70
2.35
20.80
Leverage Ratio 8.40
ProfitabilityValueIndustryS&P 500US Markets
75.90
29.00
34.50
19.50
23.87
RevenueValueIndustryS&P 500US Markets
25.49B
26.57
1.10
3.40
DividendsValueIndustryS&P 500US Markets
1.53
3.40
11.55
8.41
Payout ratio43.00
Earnings HistoryEstimateReportedSurprise %
Q01 20212.121.87-11.79
Q04 20202.352.7517.02
Q03 20201.761.54-12.50
Q02 20201.581.8919.62
Q01 20201.551.7512.90
Q04 20191.521.7313.82
Q03 20191.431.483.50
Q02 20191.461.502.74
Earnings Per EndEstimateRevision %Trend
6/2021 QR1.90-1.04Negative
9/2021 QR1.941.04Positive
12/2021 FY7.90-3.66Negative
12/2022 FY8.47-3.20Negative
Next Report Date29th Jul 2021
Estimated EPS Next Report1.90
Estimates Count3
EPS Growth Next 5 Years %14.60
Volume Overview
Volume5.61M
Shares Outstanding959.03M
Trades Count78.44K
Dollar Volume745.75M
Avg. Volume4.01M
Avg. Weekly Volume7.40M
Avg. Monthly Volume4.17M
Avg. Quarterly Volume3.68M

Eli Lilly and Company (NYSE: LLY) stock closed at 224.09 per share at the end of the most recent trading day (a -4.05% change compared to the prior day closing price) with a volume of 5.64M shares and market capitalization of 214.91B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 19500 people. Eli Lilly and Company CEO is David A. Ricks.

The one-year performance of Eli Lilly and Company stock is 55.26%, while year-to-date (YTD) performance is 32.72%. LLY stock has a five-year performance of 204.96%. Its 52-week range is between 129.21 and 235.85, which gives LLY stock a 52-week price range ratio of 88.97%

Eli Lilly and Company currently has a PE ratio of 30.20, a price-to-book (PB) ratio of 28.08, a price-to-sale (PS) ratio of 8.37, a price to cashflow ratio of 23.60, a PEG ratio of 2.32, a ROA of 13.46%, a ROC of 29.39% and a ROE of 119.77%. The company’s profit margin is 23.87%, its EBITDA margin is 34.50%, and its revenue ttm is $25.49 Billion , which makes it $26.57 revenue per share.

Of the last four earnings reports from Eli Lilly and Company, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.90 for the next earnings report. Eli Lilly and Company’s next earnings report date is 29th Jul 2021.

The consensus rating of Wall Street analysts for Eli Lilly and Company is Moderate Buy (1.67), with a target price of $208.82, which is -6.81% compared to the current price. The earnings rating for Eli Lilly and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eli Lilly and Company has a dividend yield of 1.53% with a dividend per share of $3.40 and a payout ratio of 43.00%.

Eli Lilly and Company has a Buy technical analysis rating based on Technical Indicators (ADX : 16.36, ATR14 : 6.55, CCI20 : 140.10, Chaikin Money Flow : 0.10, MACD : 8.17, Money Flow Index : 70.40, ROC : 12.48, RSI : 69.35, STOCH (14,3) : 70.86, STOCH RSI : 0.22, UO : 58.97, Williams %R : -29.15), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Aarti S. Shah (Option Excercise at a value of $0), Alfonso G. Zulueta (Option Excercise at a value of $0), Alfonso G. Zulueta (Sold 28 000 shares of value $4 640 000 ), Anat Hakim (Option Excercise at a value of $0), David A. Ricks (Option Excercise at a value of $0), Jackson P. Tai (Buy at a value of $249 759), Johna L. Norton (Option Excercise at a value of $0), Joshua Smiley (Option Excercise at a value of $0), Leigh Ann Pusey (Option Excercise at a value of $0), Melissa S. Barnes (Option Excercise at a value of $0), Melissa S. Barnes (Sold 5 000 shares of value $755 050 ), Michael B. Mason (Option Excercise at a value of $0), Michael Mason (Option Excercise at a value of $0), Myles O'Neill (Option Excercise at a value of $0), Stephen Fry (Option Excercise at a value of $0), Stephen Fry (Sold 7 204 shares of value $1 085 210 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
6 (66.67 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.44

Eli Lilly and Company

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

CEO: David A. Ricks

Telephone: +1 317 276-2000

Address: Lilly Corporate Center, Indianapolis 46285, IN, US

Number of employees: 19 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

News

Stocktwits